Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nine More Years? Sandoz Loses Again On Enbrel Biosimilar

Sandoz Has Held FDA Approval For Its Erelzi Version Since 2016

Executive Summary

Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.

You may also be interested in...



Sandoz Seeks Review Of Enbrel Ruling

Sandoz is seeking an en banc rehearing of a recent appeals court decision that stands to keep its Erelzi biosimilar etanercept rival to Enbrel off the market until 2029 in the US, claiming that the ruling provides a “playbook” for originators to extend patents beyond their legitimate terms.

Amgen Takes Almost 40% Of US Bevacizumab Market

Amgen’s biosimilar revenues were more than $350m in the second quarter of this year, as the company benefitted from the ‘innovator product’ commercialization model across its increasingly broad portfolio of biosimilars.

Biosimilars Will Lift Sandoz Following Q2 Sales Slump

Having benefited financially from the increased demand from the coronavirus pandemic in the first quarter, Sandoz saw a reversal of fortune in Q2 as sales fell by more than one-tenth as reported, as the company explained to Generics Bulletin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel